This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SMURF1 / E3 ubiquitin-protein ligase SMURF1 · IHC design guide
Design Immunohistochemistry for SMURF1
Plan paraffin SMURF1 IHC around cytoplasmic and membranous staining in glandular cells (HPA tissue IHC). This guide covers tissue controls and the catalog antibody’s 0.5–1 μg/mL IHC range (datasheet PB9892).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SMURF1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and membranous tissue staining (HPA tissue IHC) | |
| Staining pattern | Glandular cells show cytoplasmic and membranous staining (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet PB9892) | |
| Positive control | Breast+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Staining shows low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Expression regulation is not established (UniProt) | |
| Isoform / epitope | 2 isoforms, Long and Short; epitope coverage is unknown (UniProt) |
Section 1
Recommended SMURF1 IHC & IF Protocols
The catalog antibody uses heat-mediated EDTA retrieval at pH 8.0 (datasheet PB9892). Published SMURF1 IHC methods describe automated staining (PMC12941280) and an FFPE workflow (PMC5377408).
| Sample | Paraffin-embedded human intestinal cancer tissue; fixative not specified (datasheet PB9892) |
| Fixation | Image fixative and duration unreported (datasheet PB9892); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet PB9892); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet PB9892) |
| Primary antibody | Rabbit anti-SMURF1, 0.5-1μg/ml (datasheet PB9892) |
| Primary incubation | Overnight at 4 °C (datasheet PB9892) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9892) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SMURF1-positive staining in glandular cells of breast (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and membranous expression in several different tissue types. No signal in the no-primary control. |
💡Decision noteTry heat-mediated EDTA retrieval at pH 8.0 first (datasheet PB9892); the published FFPE workflow reports retrieval but does not specify its conditions (PMC5377408).
Section 2
What Is the Expected SMURF1 Staining Pattern?
SMURF1 is cytoplasmic and cell membrane associated, with no transmembrane segment (UniProt Q9HCE7 localization and topology). In paraffin IHC, expect cytoplasmic and membranous staining in several tissue types, including high staining in breast glandular cells, lung alveolar cells and bladder urothelial cells (HPA tissue IHC). HPA rates the tissue staining Approved but reports low consistency between antibody staining and RNA expression; interpret tissue comparisons cautiously (HPA tissue IHC).
| Cytoplasmic staining with some membrane accent in glandular cells. | This matches the reported pattern. Breast, cervix, fallopian tube, gallbladder and stomach glandular cells are each scored High (HPA tissue IHC). Compare compartments and cell types as well as intensity; HPA reports low consistency with RNA expression (HPA tissue IHC). |
| Predominantly nuclear staining, with little cytoplasmic or membranous signal. | This is discordant with the tissue IHC profile and warrants a specificity check (HPA tissue IHC; general IHC practice). Nucleoplasmic signal is listed as uncertain in ICC-IF, so an isolated nuclear signal should not establish the expected paraffin IHC pattern (HPA subcellular ICC-IF). |
| Strong color in cells outside the expected positive population. | First identify the stained cells: HPA scores alveolar cells High in lung and trophoblastic cells High in placenta (HPA tissue IHC). Unexpected staining may reflect cross-reactivity or endogenous detection activity; compare a no-primary control and the expected cell population (general IHC practice). |
| Diffuse color covers cells and extracellular spaces without clear boundaries. | An uninterpretable background can arise from nonspecific binding or detection activity (general IHC practice). It cannot confirm the cytoplasmic and membranous distribution or the cell-specific HPA pattern; assess a no-primary control before scoring cells (HPA tissue IHC; general IHC practice). |
| No signal in a section expected to contain high-staining cells. | Check that the relevant cells are present before calling the stain negative: breast glandular, lung alveolar and bladder urothelial cells are scored High (HPA tissue IHC). If they are present, review the staining run and a positive control (general IHC practice). |
💡Expected SMURF1 appearanceCall a result positive when the expected cells show clear cytoplasmic staining with possible membrane accent; high-scoring glandular, alveolar or urothelial cells provide comparison points (HPA tissue IHC). Diffuse background or isolated strong nuclear color is insufficient (HPA tissue IHC; general IHC practice).
| Compartment and topology | UniProt places SMURF1 in cytoplasm and at the cell membrane, despite no transmembrane segment (UniProt Q9HCE7 localization and topology). Membrane accent can therefore fit the record; a transmembrane staining requirement would overstate it (UniProt Q9HCE7 topology). |
| Choice of comparison cells | HPA scores breast and stomach glandular cells, lung alveolar cells, placental trophoblastic cells and bladder urothelial cells High (HPA tissue IHC). Adipocytes and skeletal muscle myocytes are scored Not detected; use them as pattern comparisons, not proof of absolute absence (HPA tissue IHC). |
| Tissue evidence and antibody status | The tissue profile is Approved, with low antibody-staining versus RNA consistency and unannotated endothelial staining (HPA tissue IHC). HPA055245 is IHC Approved; HPA019671 is ICC Approved with no IHC status listed (HPA antibodies). Do not transfer one antibody’s application status to the other. |
| Isoforms and target region | UniProt lists Long and Short isoforms and C2, two WW and HECT domains (UniProt Q9HCE7 isoforms and domains). No antibody epitope is supplied, so these features cannot predict which isoform or domain a particular stain detects. |
| IF/ICC comparison | Q: Should an ICC-IF image define the paraffin IHC result? A: No. Vesicles are the approved main ICC-IF location; nucleoplasm is uncertain (HPA subcellular ICC-IF). Use the cytoplasmic and membranous tissue profile to interpret paraffin IHC (HPA tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| A high-scoring comparison tissue is blank. | The expected cells may be absent from the section, or the staining run may have failed (HPA tissue IHC; general IHC practice). | Verify the relevant cells on a counterstained section, then review the positive control and general retrieval, antibody and detection steps (general IHC practice). No SMURF1-specific retrieval condition is supplied. |
| Every compartment has weak, hazy color. | Nonspecific binding or excessive detection background can obscure the reported pattern (general IHC practice; HPA tissue IHC). | Compare a no-primary control, then adjust general blocking, washing or detection conditions as indicated by that control (general IHC practice). Score only interpretable cell-associated signal. |
| Color persists when the primary antibody is omitted. | Endogenous detection activity or reagent background may contribute to the signal (general IHC practice). | Check the detection-system controls and address the implicated activity using the system’s standard controls and blocking steps (general IHC practice). Do not count that color as SMURF1. |
| Strong nuclear staining dominates the section. | This differs from the cytoplasmic and membranous tissue profile; the additional nucleoplasmic ICC-IF location is uncertain (HPA tissue IHC; HPA subcellular ICC-IF). | Inspect no-primary and positive controls and confirm whether cytoplasmic or membrane signal is present in expected cells (general IHC practice; HPA tissue IHC). Avoid scoring nuclear color alone. |
| Endothelial staining is prominent. | HPA flags endothelial antibody staining as unannotated and reports low staining-versus-RNA consistency (HPA tissue IHC). | Record endothelial signal separately from the expected cell populations and compare controls and morphology (general IHC practice; HPA tissue IHC). Avoid treating it as validated SMURF1 localization. |
| An ICC-IF pattern appears different from paraffin IHC. | ICC-IF lists approved vesicles and uncertain nucleoplasm, while tissue IHC describes cytoplasmic and membranous expression (HPA subcellular ICC-IF; HPA tissue IHC). | Interpret each application against its own HPA profile and antibody status: HPA055245 is IHC Approved; HPA019671 is ICC Approved (HPA antibodies). Do not use the ICC-IF observation as an IHC protocol option. |
Experiment evidence
IHC & IF images showing SMURF1 staining
PB9892 · IHCIHC analysis of SMURF1 using anti-SMURF1 antibody (PB9892). SMURF1 was detected in paraffin-embedded section of human intestinal cancer tiss
PB9892 · IHCIHC analysis of SMURF1 using anti-SMURF1 antibody (PB9892). SMURF1 was detected in paraffin-embedded section of human breast cancer tissue.
PB9892 · IFIF analysis of SMURF1 using anti-SMURF1 antibody (PB9892). SMURF1 was detected in immunocytochemical section of Hela cells. Enzyme antigen r
A02823 · IHCImmunohistochemistry of SMURF1 in rat kidney tissue with SMURF1 antibody at 5 μg/ml.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000198742-SMURF1/tissue/cerebral+cortex#imid_19205807
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000198742-SMURF1/tissue/colon#imid_19205741
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000198742-SMURF1/tissue/liver#imid_19205750
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000198742-SMURF1/tissue/kidney#imid_19205751
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA019671; green = SMURF1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA019671; green = SMURF1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SMURF1 IHC & IF
🧪Run breast first: its glandular cells should stain (HPA: High in breast glandular cells). Use adipose tissue as a negative comparator (HPA: Not detected in adipocytes); on the breast slide, treat unstained cells outside the glandular compartment as an internal background reference, without assuming every such cell is SMURF1-negative.
Positive control tissue: Breast (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SMURF1 in A-431, U-251MG, U2OS, with annotated localisation: Vesicles (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; an isotype control matched to the primary antibody’s host species and clonality; and a validated SMURF1 knockout section or peptide-block control (standard IHC practice). For breast sections, quench endogenous peroxidase and check endogenous biotin background when using the caption’s biotin-based DAB detection (PB9892 tissue-IHC caption: biotinylated secondary, SABC and DAB).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the exact PB9892 tissue-IHC caption does not state a fixative. The caption uses heat retrieval in EDTA at pH 8.0 for a paraffin section, but does not establish that retrieval is required (PB9892 tissue-IHC caption). The supplied evidence does not show whether frozen sections or IF are easier, or identify a breast-specific artefact.
HPA tissue IHC evidence for SMURF1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data. Antibody staining in endothelial cells not annotated, view images.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Cervix | Glandular cells | High | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | High | Protein (IHC) | HPA → |
| Gallbladder | Glandular cells | High | Protein (IHC) | HPA → |
| Lung | Alveolar cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Lymph node | Germinal center cells | Not detected | Protein (IHC) | HPA → |
| Oral mucosa | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SMURF1 IHC Tips
SMURF1 IHC troubleshooting focuses on retrieval, compartment-aware scoring, and control tissues because reported staining is cytoplasmic and membranous (HPA tissue IHC).
What retrieval should I use when SMURF1 staining is weak in paraffin sections?
Start with heat-mediated retrieval in EDTA at pH 8.0 for the catalog antibody (datasheet PB9892). The selected paraffin-section example used that retrieval before 1 µg/ml primary antibody overnight at 4°C (datasheet PB9892). If signal remains weak, check that sections stayed covered during heating and compare retrieval conditions on adjacent sections while keeping detection and exposure to chromogen constant (standard IHC practice). Include a tissue and cell population with reported staining, such as breast glandular cells, to distinguish a failed run from a low-signal specimen (HPA: High in breast glandular cells). Do not treat a stronger result after harsher retrieval as proof of specificity (standard IHC practice).
Could fixation explain variable SMURF1 staining between paraffin blocks?
Target-specific sensitivity of SMURF1 to fixation is unknown from the supplied evidence; the selected paraffin-section caption does not state a fixative (datasheet PB9892). Record each block’s fixative, fixation duration, processing history, and section age before comparing staining across blocks (standard IHC practice). Process comparison sections together using EDTA at pH 8.0 and the same primary antibody concentration, 1 µg/ml, when following the selected example (datasheet PB9892). Assess a reported positive cell population and tissue morphology in each run, since damaged or poorly preserved areas can distort chromogenic scoring (HPA: High in breast glandular cells; standard IHC practice). Avoid assigning a SMURF1-specific fixation effect without a controlled comparison (standard IHC practice).
Should I accept nuclear or sharply membrane-restricted SMURF1 staining as specific?
Expect primarily cytoplasmic and membranous staining across tissue types when interpreting chromogenic sections (HPA tissue IHC: cytoplasmic and membranous expression). SMURF1 has no transmembrane segment, so a membrane-associated signal does not imply that the protein spans the membrane (UniProt Q9HCE7 topology). Vesicles are the approved main location in HPA cell imaging, while nucleoplasmic localisation is listed as uncertain; use those observations as context rather than direct tissue-IHC validation (HPA subcellular). Compare staining with cell boundaries and a counterstain, and inspect the same compartment in a reported positive tissue (standard IHC practice; HPA: High in breast glandular cells). Predominantly nuclear-only staining warrants additional specificity checks (HPA tissue IHC; standard IHC practice).
Can this antibody distinguish SMURF1 isoforms or reveal an inaccessible epitope?
The record lists Long and Short SMURF1 isoforms, but the supplied IHC caption does not identify the antibody’s epitope or establish isoform selectivity (UniProt Q9HCE7 isoforms; datasheet PB9892). SMURF1 contains a C2 domain, 2 WW domains, and a HECT domain; domain boundaries alone cannot show which isoform the antibody detects (UniProt Q9HCE7 domains; standard antibody interpretation). Keep the EDTA pH 8.0 retrieval and staining conditions constant when comparing specimens (datasheet PB9892; standard IHC practice). If staining differs despite comparable processing, seek documented epitope mapping or an independent antibody before calling an isoform-specific pattern (standard IHC practice). Record compartment and cell type alongside intensity so a distribution change is not mistaken for isoform recognition (standard IHC practice).
How should IF evidence inform a multiplex experiment alongside SMURF1 chromogenic IHC?
Use the IF/ICC guide for its own experimental workflow; the paraffin-section example establishes a chromogenic IHC result for PB9892 only (datasheet PB9892). For a multiplex IF experiment, pair SMURF1 with a validated marker of the expected cell type and inspect whether signals occupy the same cells (standard IF practice; HPA: High in breast glandular cells). Choose a fluorophore channel that separates the intended signal from measured tissue autofluorescence, with single-label and unstained controls (standard IF practice). SMURF1 has no transmembrane segment and is reported in cytoplasm and at the cell membrane; permeabilisation should therefore be assessed for intracellular epitope access once the antibody’s epitope is known (UniProt Q9HCE7 topology and localisation; standard IF practice). HPA cell imaging reports vesicles as its approved main location (HPA subcellular).
How can I reduce diffuse brown background without losing SMURF1 signal?
First compare stained sections with a no-primary control and examine whether brown signal follows tissue edges, damaged regions, or expected cells (standard IHC practice). The selected example used 10% goat serum blocking, 1 µg/ml primary antibody overnight at 4°C, and a biotinylated secondary with DAB development (datasheet PB9892). If background is diffuse, reassess blocking, washing, primary concentration, and chromogen development on matched sections one variable at a time (standard IHC practice). Include an appropriate peroxidase block for DAB detection and assess endogenous biotin when using a biotin-based detection system; these are general workflow controls, not SMURF1-specific findings (standard IHC practice). Preserve a reported positive cell population to check that background reduction has not erased plausible signal (HPA: High in breast glandular cells).
How should I score SMURF1 staining when cell types differ within a section? ⚠ ANSWER MARKED FOR VERIFICATION
Define the target cell population and cytoplasmic or membranous compartment before scoring; reported SMURF1 tissue staining spans both compartments (HPA tissue IHC). For each region, record the percentage of positive target cells and an intensity category, then calculate an H-score from 0–300 if intensity is reproducible (standard IHC practice). Alternatively, report positive-cell density per mm² of viable target tissue when cell abundance varies across regions (standard IHC practice). Normalise to the number or area of eligible target cells rather than total section area, and exclude necrosis and processing defects using consistent rules (standard IHC practice). Report glandular and other cell populations separately where applicable, since HPA staining levels are cell-type specific (HPA tissue IHC).
What distinguishes genuine SMURF1 positivity from artefact in a paraffin section?
A plausible positive pattern lies in the cytoplasm or along cell membranes of intact cells, consistent with reported tissue staining and SMURF1 localisation (HPA tissue IHC; UniProt Q9HCE7 localisation). Check the relevant cell type: HPA reports High staining in breast glandular cells but no detection in adipocytes, making compartment and cell identity more informative than brown colour alone (HPA tissue IHC). Exclude edge accentuation, necrotic deposits, and signal reproduced in a no-primary control before interpreting intensity (standard IHC practice). For DAB detection, verify peroxidase blocking and assess detection-system background, especially with the example’s biotin-based chemistry (datasheet PB9892; standard IHC practice). Treat a discordant result cautiously because HPA notes low consistency between antibody staining and RNA expression data (HPA reliability description).
Boster reagents
Best SMURF1 / E3 ubiquitin-protein ligase SMURF1 IHC Antibodies
Two anti-SMURF1 antibodies have tissue IHC images: human paraffin sections and rat kidney tissue; one also has IF data in HeLa cells (catalog images: PB9892, A02823).
Real IHC data
Anti-SMURF1 Antibody ®
Cat # PB9892
Real IHC data
Anti-SMURF1 Antibody
Cat # A02823
PB9892 shows IHC in paraffin sections of human intestinal and breast cancer tissue and IF in HeLa cells (PB9892 image captions). A02823 shows IHC in rat kidney tissue; its listed reactivity includes human, mouse and rat (A02823 image caption and catalog).
Which to pick: For human paraffin-section IHC, choose PB9892: its IHC image captions show that processing, while the fixative is unreported (PB9892 image captions). For IF/ICC, choose PB9892, which lists both applications and shows IF in HeLa cells (PB9892 catalog and IF image caption). For a mouse-reactive option, consider A02823, but its pictured IHC evidence is from rat kidney; clone type is unreported for both antibodies (A02823 catalog and image caption; PB9892 catalog).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9HCE7 (SMUF1_HUMAN, E3 ubiquitin-protein ligase SMURF1).
- Human Protein Atlas. SMURF1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. SMURF1 subcellular location (ICC-IF): Mainly localized to vesicles. In addition localized to the nucleoplasm..
- Human Protein Atlas. SMURF1 antibody validation summary (2 antibodies).
- SMURF1 Downregulation Highlights Its Potential Role in Breast Cancer. International journal of molecular sciences 2026 — PMC12941280.
- Ubiquitin ligase SMURF1 functions as a prognostic marker and promotes growth and metastasis of clear cell renal cell carcinoma. FEBS open bio 2017 — PMC5377408.
- Smurf1 silencing restores PTEN expression that ameliorates progression of human glioblastoma and sensitizes tumor cells to mTORC1/C2 inhibitor Torin1. iScience 2021 — PMC8666673.
- The Ubiquitin Ligase Smurf1 Functions in Selective Autophagy of Mycobacterium tuberculosis and Anti-tuberculous Host Defense. Cell host & microbe 2017 — PMC5699477.
- PubMed PMID:10997877 — UniProt-cited evidence.
- PubMed PMID:12853948 — UniProt-cited evidence.
- PubMed PMID:12690205 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SMURF1 (E3 ubiquitin-protein ligase SMURF1). Expected localisation Cytoplasmic and membranous tissue staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet PB9892). Validated IHC antibody: PB9892 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Breast (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human intestinal cancer tissue; fixative not specified (datasheet PB9892); 2. Fixation: Image fixative and duration unreported (datasheet PB9892); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet PB9892); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet PB9892); 8. Primary antibody: Rabbit anti-SMURF1, 0.5-1μg/ml (datasheet PB9892); 9. Primary incubation: Overnight at 4 °C (datasheet PB9892). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Staining shows low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 2 isoforms, Long and Short; epitope coverage is unknown (UniProt); Regulation: Expression regulation is not established (UniProt). Evidence: UniProt Q9HCE7, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to vesicles. In addition localized to the…, Datasheet PB9892, PMC12941280, PMC5377408. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SMURF1/immunohistochemistry-ihc-guide.